Approaches to the treatment of multiple sclerosis

Chemist Dr.Doping tells about the action Copaxone, Epstein - Barr virus and pre-clinical trials of new drugs.

What is the history of research of multiple sclerosis? How is the disease? What today there are approaches to its treatment? And as multiple sclerosis is associated with Epstein - Barr virus?

The history of the study of multiple sclerosis has more than 100 years. 150 years ago, the first cases of the disease have been described. Multiple sclerosis is a serious disease that requires heavy loads on a budget. In all developed countries, in Russia, drug provision of these patients covered by the state budget, it is very expensive. Patients live longer, they are socially maladjusted, they have great mental ability, and they are, in principle, can work. But the difficulty lies in the fact that the disease is developing in leaps and bounds, the episodes. Death occurs when the total demyelination, when the disease affects the central nervous system of the machine. And the main problem is that the etiology is unknown.

The immunoglobulin gene library was created in our lab, that is, representing the entire immunologic repertoire person with multiple sclerosis. By screening these libraries assay specificity to various autoantigens it has been shown that some antibodies reacting with fragments of myelin basic protein, also interact with proteins of the virus, Epstein - Barr virus. We have clearly shown that Epstein - Barr signed in the repertoire of the patient. You can say, "Epstein - Barr virus affects so many people in the world, and multiple sclerosis patients are relatively few." There are important presentation of antigens, the basis of antigen degradation, ie susceptibility immunogenetic human machine. Probably, consider these two aspects - virus infection and immunogenetics particular person - can help uncover the causes of the disease. In this case it is particularly important for new approaches of personalized medicine. To reduce multiple sclerosis – buy Cogitum, Cerebrolysin, Semax and Nootropil.

One of the possible directions of therapy is to create a more specific drug for the treatment of multiple sclerosis than Copaxone. some formulation of peptide fragments of myelin basic protein was created in our lab, which were packaged in liposomes. Preclinical tests (tests on mice that used the model of mice and rats, developing experimental autoimmune encephalomyelitis EAE) have shown that the drug is promising.